Adding the selective oestrogen-receptor downregulator fulvestrant to the aromatase inhibitor anastrozole in the first-line setting significantly extends long-term progression-free survival (PFS) and overall survival (OS) compared with anastrozole alone in postmenopausal women with hormone-receptor (HR)-positive metastatic breast cancer, according to the final results of the S0226 trial.
Flare rates appear to be similar after tapering of a tumour necrosis factor (TNF) inhibitor or a conventional synthetic disease-modifying antirheumatic drug (csDMARD) up to 9 months in patients with rheumatoid arthritis (RA) who have achieved disease control, with a nonsignificant 10-percent difference in flare rates after 1 year in favour of csDMARDs, according to data from the TARA* study.
Treatment with 300-mg secukinumab confers benefits among patients with palmoplantar pustular psoriasis (PPP) in terms of Palmoplantar Psoriasis Area and Severity Index (PPPASI75) responses over 52 weeks and improved quality of life (QOL), results of the 2PRECISE study have shown.
Patients with EGFR-positive non-squamous non-small-cell lung cancer (NSCLC) had greater progression-free survival (PFS) when treated with erlotinib plus bevacizumab rather than erlotinib alone, according to an interim analysis of the phase III NEJ026 trial.
The antiplatelet drug clopidogrel, used alone or in combination with low-dose aspirin, cuts the risk of colorectal cancer by a magnitude comparable to that conferred by low-dose aspirin monotherapy, with the risk reduction apparent at 1 year of treatment, according to a study.
Careful management of drug waste and use of “drug day,” through proper vial selection and the ability to use the leftover drug, can lead to cost savings, according to a study describing the economic management of the high-cost anticancer drug ipilimumab in Italian reference centres.
Patients with chronic hepatitis B virus (HBV) infection treated with the nucleot(s)ide analogue tenofovir disoproxil fumarate (TDF) had a lower risk of hepatocellular carcinoma (HCC) than those treated with entecavir, according to data from a large observational study presented at ILC 2019.
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.
Use of a short regimen in the treatment of rifampin-resistant tuberculosis (TB) infection is noninferior to a long regimen in terms of efficacy and comparable with respect to safety, according to the results of the phase III STREAM* trial.
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Patients on the anticoagulant drug edoxaban could safely continue their treatment while undergoing certain procedures, with a low incidence of bleeding and cardiovascular events reported in the prospective EMIT AF/VTE* study.